North America Chinese Hamster Ovary (CHO) Cells Market, By Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System and Others), Application (Biologics and Medical Research), End User (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others) - Industry Trends and Forecast to 2030.
North America Chinese Hamster Ovary (CHO) Cells Market Analysis and Insights
One significant driver of the CHO cell market is the continued growth of monoclonal antibodies (mAbs) in the pharmaceutical industry. CHO cells are integral to producing mAbs, which treat various diseases, including cancer and autoimmune disorders. The expansion of mAb-based therapies and ongoing research and development in this field have fueled the demand for CHO cells. The market also benefits from increased research and development efforts to improve cell line development and bioprocess optimization. These advancements help enhance the efficiency and productivity of CHO cell-based biomanufacturing, reducing production costs and timelines.
However, the market faces challenges such as the high cost of maintaining CHO cultures, lack of skilled personnel, and complex regulatory requirements.
The North America Chinese Hamster Ovary (CHO) cells market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.3% in the forecast period of 2023 to 2030 and is expected to reach USD 263,069.07 thousand by 2030 from USD 143,106.10 thousand in 2022.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand, ASP in USD, and Volume in Units
|
|
Segments Covered
|
Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System and Others), Application (Biologics and Medical Research), End User (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc., AcceGen, RayBiotech Life, Inc., CLS Cell Lines Service GmbH, BPS Bioscience, Inc., GenTarget Inc., Merck KGaA, Promega Corporation, Abeomics, Applied Biological Materials Inc. (abm), ATCC, Sartorius AG, Lonza, Horizon Discovery Ltd., Cytiva, and Curia Global, Inc.
|
North America Chinese Hamster Ovary (CHO) Cells Market Definition
Chinese hamster ovary (CHO) cells are a mammalian cell line commonly used in biotechnology and biomedical research, particularly in cell culture and bioprocessing. These cells have become essential tools in biotechnology and biomedical research. CHO cells are known for their adherence to culture surfaces, robust growth characteristics, and ability to express recombinant proteins. Their popularity stems from their similarity to human cells, making them suitable for studying biological processes and producing biopharmaceuticals.
North America Chinese Hamster Ovary (CHO) Cells Market Dynamics
This section deals with understanding the market drivers, advantages, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Use of CHO Cells in the Genetic Study
CHO cells are an epithelial cell line derived from the Chinese hamster ovary commonly used in biological and medical research and commercially to produce therapeutic recombinant DNA proteins. They have found widespread use in genetics, toxicity screening, nutrition, and gene expression studies, especially recombinant protein expression. CHO cells are the most commonly used mammalian host for the industrial production of recombinant protein drugs.
The increasing use of CHO cells in genetic studies reflects their unique advantages in genetic research.
CHO cells are renowned for their genetic stability. This means their genetic makeup remains relatively constant across multiple cell generations, making them an excellent choice for genetic studies. Researchers can confidently manipulate and study specific genes or genetic modifications without the concern of unexpected genetic changes interfering with their experiments. This stability is particularly crucial when conducting precise gene editing, knockout studies, or investigating the long-term effects of genetic modifications.
- Growing Demand for Biopharmaceuticals
One significant driver of the demand for biopharmaceuticals is their effectiveness. These drugs have demonstrated remarkable therapeutic outcomes in oncology, autoimmune diseases, and rare genetic disorders. For instance, monoclonal antibodies, a common type of biopharmaceutical, have transformed cancer treatment by targeting cancer cells directly while sparing healthy ones. Biopharmaceuticals also offer promising approaches to managing previously untreatable conditions and rare diseases, often neglected by traditional drug development due to their limited patient populations.
Opportunity
-
Continuous Development of Cell Culture Technologies
The continuous development of cell culture technologies is of paramount importance in the realms of biopharmaceutical manufacturing and biotechnology research. This ongoing evolution is pivotal in enhancing the production of various critical products, including biological drugs, vaccines, and other biotechnological substances. Cell culture technologies involve growing and maintaining cells derived from living organisms in controlled environments, typically in laboratory settings. These cultured cells are the foundational building blocks for producing a wide range of biopharmaceuticals and biotechnology products. The significance of this advancement lies in its ability to provide a scalable and consistent source of cells that can be engineered to express specific proteins or therapeutic agents. These cultured cells are integral in biologics, such as monoclonal antibodies, vaccines, gene therapies, and regenerative medicines. The continuous improvement in cell culture technologies leads to higher yields, increased efficiency, reduced production costs, and improved product quality, ultimately benefitting both the healthcare industry and patients who rely on these innovative therapies. Moreover, it facilitates the exploration of new frontiers in biotechnology research, enabling scientists to study cell behavior, disease mechanisms, and drug development, ultimately pushing the boundaries of scientific knowledge and medical advancements.
Restraints/ Challenges
-
High-Cost of CHO Cell-Based Production
The high cost of Chinese hamster ovary (CHO) cell-based production is a significant restraint within the biopharmaceutical manufacturing industry. Several factors contribute to the elevated costs.
The upstream process in CHO cell-based production is complex. It involves cultivating mammalian cells in bioreactors, necessitating strict control over various parameters such as temperature, pH, oxygen levels, and nutrient supply. Maintaining these optimal conditions for cell growth and protein expression requires specialized equipment and skilled personnel, adding to the overall cost.
- Time-Consuming and Inconsistency in the CHO Cell Line Development Process
The development of CHO cell lines for biopharmaceutical production is a complex and time-consuming process often marked by variability and challenges. This process begins with introducing specific genes or genetic modifications into CHO cells, enabling them to express and produce the desired biological drug or protein. However, this initial step can be inefficient, as not all cells will successfully incorporate the genetic material, leading to variability in protein expression levels.
Recent Developments
- In July 2023, Lonza launched TheraPRO CHO Media System, a new cell culture medium that simplifies processes and optimizes productivity and protein quality when using GS-CHO cell lines. The startup supports pharmaceutical and biotech companies producing therapeutic proteins to further improve product quality. The TheraPRO CHO Media System provides efficient performance, achieving high concentrations of viable cells and protein titers above 5 g/L over a 15-day culture period. This represents more than double the protein titer that can be produced with commercially available solutions. This launch has helped the company to expand its product portfolio in the market.
- In July 2023, Merck announced that it is expanding its facility in Lenexa, Kansas, U.S., adding 9,100 square meters of laboratory space and production capacity for the production of cell culture media. This expansion makes Lenexa the company's largest dry powder cell culture facility and a center of excellence in North America. The investment in the region reflects the company's strategy to expand and diversify its supply chain to meet current and future demand for cell culture platforms.
- In June 2023, Curia, a leading contract research, development, and manufacturing company announced that it has signed a license agreement with North American life sciences company MilliporeSigma, Merck KGaA in Darmstadt, Germany, which will allow Curia and its customers to use CHOZN. GS-/- cell line for the production of proteins and antibodies for therapeutic purposes. Following the agreement, the CHOZN GS-/- cell line will be integrated into Curia's cell line development workflow and immediately available to Curia's customers.
- In October 2022, Thermo Fisher Scientific Inc. collaborated with ProBioGen to develop an even better platform the Gibco Freedom ExpiCHO-S Cell Line Development Kit. This kit allows users to generate cell lines suitable for clinical development without their own original cells, vectors, or previous experience in the field. ProBioGen significantly contributed to the performance of the Freedom ExpiCHO-S kit by leveraging its strong expertise in cell line and process development. The new series utilizes Thermo Fisher's ExpiCHO-S cell line expanding the company's product portfolio for the CHO cell line development series.
- In February 2022, Sartorius AG acquired business from Novasep, added a complementary offering to its chromatography portfolio. The acquired portfolio includes chromatography systems primarily suited for small biomolecules such as oligonucleotides, peptides, and insulin, and innovative systems for the continuous production of biopharmaceuticals.
North America Chinese Hamster Ovary (CHO) Cells Market Scope
North America Chinese Hamster Ovary (CHO) cells market is categorized into five notable segments based on type, system, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Services
- Product
On the basis of type, the market is segmented into services and product.
System
- Metabolic Selection System
- Antibiotic Selection System
- Others
On the basis of system, the market is segmented into metabolic selection system, antibiotic selection system, and others.
Application
- Biologics
- Medical Research
On the basis of application, the market is segmented into biologics and medical research.
End User
- Biopharmaceutical Companies
- Biotechnology Companies
- Clinical Development and Manufacturing Organizations
- Clinical Research Organizations
- Academic Institutes and Research Organizations
- Others
On the basis of end user, the market is segmented into biopharmaceutical companies, biotechnology companies, clinical development and manufacturing organizations, clinical research organizations, academic institutes and research organizations, and others.
Distribution Channel
- Direct Tenders
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tenders, retail sales, and others.
North America Chinese Hamster Ovary (CHO) Cells Market Regional Analysis/Insights
The market is categorized into five notable segments, such as type, system, application, end user, and distribution channel.
The countries covered in this market report are U.S., Canada, and Mexico.
U.S. is expected to dominate due to the presence of key market players in the largest consumer market with high GDP and rise in technological advancement in CHO cell products.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Chinese Hamster Ovary (CHO) Cells Market Share Analysis
North America Chinese Hamster Ovary (CHO) cells market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points are only related to the company's focus on the market.
Some of the major players operating in the North America Chinese Hamster Ovary (CHO) cells market are Thermo Fisher Scientific Inc., AcceGen, RayBiotech Life, Inc., CLS Cell Lines Service GmbH, BPS Bioscience, Inc., GenTarget Inc., Merck KGaA, Promega Corporation, Abeomics, Applied Biological Materials Inc. (abm), ATCC, Sartorius AG, Lonza, Horizon Discovery Ltd., Cytiva, and Curia Global, Inc. among others.
SKU-